Telitacicept beneficial in childhood-onset SLE
In the management of patients with childhood-onset systemic lupus erythematosus (cSLE), combining telitacicept with standard of care (SoC) appears to reduce disease activity, steroid exposure, and immunological marker concentrations, effects comparable to those observed with belimumab, according to a study.
